World journal of clinical oncology最新文献

{"title":"Early detection of gallbladder cancer: Current status and future perspectives.","authors":"Yajnadatta Sarangi, Ashok Kumar","doi":"10.5306/wjco.v16.i7.107781","DOIUrl":"10.5306/wjco.v16.i7.107781","url":null,"abstract":"<p><p>Gall bladder cancer (GBC) remains a highly aggressive disease, with an overall 5-year dismal survival rate of 15%-20%. Its asymptomatic nature in very early stages and non-specific clinical presentations pose significant challenges to timely detection. Consequently, GBC often presents late, making it one of the most challenging cancers to manage. Surgery offers the best chance for long-term survival; however, only 10% of GBC patients are candidates for upfront resection, with the majority presenting in locally advanced or metastatic stages. Furthermore, GBC is generally resistant to chemotherapy and radiotherapy, limiting the effectiveness of systemic therapy. Therefore, early diagnosis is crucial to offer the best treatment through surgical resection and to improve the outcome. Recent advancements in imaging technologies, biomarker discovery, and molecular diagnostics offer promising avenues for enhancing detection rates. Though non-invasive, most of them lack specificity, and the majority fail as an early diagnostic tool. This review examines the current status of early detection strategies for GBC, addresses the limitations of existing approaches, and explores the newer emerging diagnostic tools and techniques and how they can be exploited in future for its early detection.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107781"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compound lidocaine cream with warm compress for pain relief in ultrasound-guided peripherally inserted central catheter placement for cancer patients.","authors":"Yan Wang, Xue-Ni Yang, Sheng Ji, Yu-Mei Zhang, Yi Wang, Yan-Mei Wang, Yue-Xia Gu","doi":"10.5306/wjco.v16.i7.108173","DOIUrl":"10.5306/wjco.v16.i7.108173","url":null,"abstract":"<p><strong>Background: </strong>Ultrasound-guided peripherally inserted central catheter (PICC) placement is vital for cancer therapy, but lidocaine infiltration faces limitations like puncture pain and vasospasm.</p><p><strong>Aim: </strong>To assess the clinical efficacy of a no-pain intervention-combining compound lidocaine cream with warm compress-in reducing pain during ultrasound-guided PICC placement in cancer patients.</p><p><strong>Methods: </strong>A retrospective cohort study analyzed 88 cancer patients undergoing PICC placement (Shanghai Fourth People's Hospital, 2024). Patients were divided into control (lidocaine infiltration, <i>n</i> = 44) and intervention (cream + warm compress, <i>n</i> = 44) groups. Primary outcomes: Pain scores (numerical rating scale), procedural time, complications; secondary outcome: Satisfaction.</p><p><strong>Results: </strong>The intervention group showed significantly lower pain scores (1.2 ± 0.4 <i>vs</i> 3.8 ± 1.2, <i>P</i> = 0.012) with comparable first-attempt success (95.5% <i>vs</i> 90.9%) and safety (<i>P</i> = 0.672). Thermal activation of transient receptor potential vanilloid 1 channel enhanced drug penetration, achieving anesthesia within 8-10 minutes. Patient satisfaction reached 97.7%.</p><p><strong>Conclusion: </strong>The combination of compound lidocaine cream with warm compress significantly alleviates procedural pain and enhances patient satisfaction during ultrasound-guided PICC placement in cancer patients, supporting its clinical application.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108173"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and advances in the treatment of colorectal cancer with liver metastases.","authors":"Wei-Xing Liu, Chuang Jiang, Jia-Xin Li","doi":"10.5306/wjco.v16.i7.107438","DOIUrl":"10.5306/wjco.v16.i7.107438","url":null,"abstract":"<p><p>The incidence of colorectal cancer is gradually increasing, and a majority of patients are diagnosed with distant metastases at the time of initial diagnosis, with the liver being the most common site of metastasis. Unlike most malignant tumors, patients with distant metastases can still achieve favorable prognoses if both the primary tumor and liver metastases are surgically resected. With advances in systemic therapies, many patients with initially unresectable liver metastases from colorectal cancer can undergo systemic treatment to achieve conversion therapy, thereby gaining the opportunity for surgery. However, there is still no consensus on several issues, including the timing of systemic therapy before and after surgery, whether neoadjuvant therapy should be employed, and the choice between simultaneous or staged surgeries. This review aims to systematically describe the current treatment landscape for colorectal cancer with liver metastases and highlight several unresolved controversial issues, providing valuable insights for the diagnosis and treatment of colorectal liver metastases.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107438"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived risk of gastric cancer associated with long-term use of proton pump inhibitors: Bridging the gap.","authors":"Ibrahim O Sawaied, Abraham O Samson, Efrat Golan","doi":"10.5306/wjco.v16.i7.107091","DOIUrl":"10.5306/wjco.v16.i7.107091","url":null,"abstract":"<p><strong>Background: </strong>Long-term use of proton pump inhibitors (PPIs) has been associated with potential adverse effects, including an increased risk of gastric cancer. Despite widespread use awareness of these risks among physicians varies considerably. Understanding physicians' perceptions and prescribing behaviors is critical to improving patient safety and promoting evidence-based practices. This study aimed to assess the level of awareness and risk perception among gastroenterologists and non-gastroenterologists regarding prolonged PPI use and its association with gastric malignancy.</p><p><strong>Aim: </strong>To assess physicians' awareness of gastric cancer risk associated with long-term PPI use and compare perceptions between specialties.</p><p><strong>Methods: </strong>A cross-sectional observational study was conducted among 33 physicians (15 gastroenterologists and 18 non-gastroenterologists) in Israel. Participants completed a structured questionnaire evaluating knowledge, attitudes, and prescribing behaviors related to PPI use. Data were analyzed using descriptive statistics and nonparametric tests to assess differences between groups and correlation patterns. Ethical approval and informed consent were obtained.</p><p><strong>Results: </strong>Gastroenterologists demonstrated significantly higher awareness of the potential gastric cancer risks linked to prolonged PPI use (mean awareness score: 6.9 ± 1.2) compared with non-gastroenterologists (4.1 ± 1.3, <i>P</i> < 0.01). Despite their awareness 80% of gastroenterologists reported frequent long-term prescribing. Nonparametric correlation analysis revealed associations between specialty, knowledge level, and prescribing habits. Several misconceptions about cancer risk mechanisms were identified across specialties.</p><p><strong>Conclusion: </strong>Physician awareness regarding gastric cancer risk of long-term PPI use remains inconsistent, especially among non-specialists, emphasizing the need for targeted educational programs and clearer prescribing guidelines.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107091"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging knowledge gaps in breast cancer prevention: Insights from Ethiopia.","authors":"Shan Zhou","doi":"10.5306/wjco.v16.i7.106687","DOIUrl":"10.5306/wjco.v16.i7.106687","url":null,"abstract":"<p><p>This editorial comment on the article by Agidew <i>et al</i> in the recent issue of the <i>World Journal of Clinical Oncology</i>. Breast cancer remains a growing challenge in Ethiopia, where high mortality results from low awareness, delayed diagnosis, and restricted healthcare access. Agidew <i>et al</i> report that women with a family history of breast disease exhibit significantly higher levels of knowledge (83.9% <i>vs</i> 10.5%), more positive attitudes (49% <i>vs</i> 32.1%), and greater engagement in preventive practices (74.1% <i>vs</i> 16.7%). However, with 69%-79% of women living below the poverty line, socioeconomic barriers severely limit preventive actions. Education, income, and community health insurance emerge as key predictors of health behaviors. We propose integrated interventions including deploying community-based approaches, culturally tailored education, and artificial intelligence-powered education tools, to bridge knowledge gaps and transform awareness into action. This multifaceted strategy offers a scalable model for resource-limited settings globally, addressing both individual awareness and structural barriers to improve breast cancer outcomes.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"106687"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early identification and prevention of depressive symptoms in breast cancer patients.","authors":"De-Hui Li, Chang Qiao, Xiao-Tong Tian, Jian-Li Ge","doi":"10.5306/wjco.v16.i7.106792","DOIUrl":"10.5306/wjco.v16.i7.106792","url":null,"abstract":"<p><p>Breast cancer ranks among the most prevalent cancers worldwide, particularly affecting young and middle-aged women, who face higher recurrence rates, lower survival rates, and substantial psychological health challenges. Depressive symptoms, frequently observed in breast cancer patients, significantly influence treatment outcomes and quality of life. Recent years have seen a growing focus on these symptoms, emphasizing early identification and intervention. This editorial comments on the recent study by Mao <i>et al</i> on a risk prediction model for depression in young and middle-aged breast cancer patients. Research suggests that factors such as tumor grade, monthly income, pain perception, family support, and physical activity critically influence the onset of depressive symptoms. By developing personalized risk prediction models, it becomes possible to identify high-risk patients early, allowing healthcare professionals to implement preventive strategies proactively. The editorial advocates for increased attention and resources dedicated to psychological health interventions for breast cancer patients, aiming to foster comprehensive care strategies that mitigate the impacts of depression and enhance overall quality of life.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"106792"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular mechanisms of thymopoietin in papillary thyroid cancer: Multiplatform gene expression data, gene knockout screening, and in-house immunohistochemistry.","authors":"Chang Song, Yu-Yan Pang, Shang-Yi Lu, Bin Li, Dong-Ming Li, Rong-Quan He, Di-Yuan Qin, Shi-De Li, Ning Qv, Yan-Mei Chen, Gang Chen, Juan He, Xiao-Bo Jiang","doi":"10.5306/wjco.v16.i7.107109","DOIUrl":"10.5306/wjco.v16.i7.107109","url":null,"abstract":"<p><strong>Background: </strong>Although thymopoietin (TMPO) has been elucidated to be overexpressed in cancers, its underlying mechanisms are not yet fully understood.</p><p><strong>Aim: </strong>To investigate the expression and clinical significance of TMPO in papillary thyroid carcinoma (PTC).</p><p><strong>Methods: </strong>Databases such as Gene Expression Omnibus, The Cancer Genome Atlas Program-Genotype-Tissue Expression, The Human Protein Atlas (THPA), and tissue microarrays were screened. Immunohistochemical staining scores and standardized mean difference were used to calculate expression levels, and summary receiver operating characteristic curves were plotted to evaluate diagnostic performance. A Gene Set Enrichment Analysis enrichment analysis was conducted to identify TMPO-related signaling pathways. A protein interaction network was constructed to identify hub genes. The impact of TMPO on PTC cell proliferation and the effects of its knockout were analyzed using clustered regularly interspaced short palindromic repeats (CRISPR) knockout screening and the Cancer Cell Line Encyclopedia database.</p><p><strong>Results: </strong>The TMPO protein was significantly overexpressed in PTC tissues, primarily localized in the cytoplasm and nuclear membrane. The mRNA level analysis showed mild overexpression of TMPO in PTC tissues, with a certain discriminatory value (area under the curve = 0.66). TMPO may promote cancer through involvement in cell adhesion, focal adhesion, leukocyte migration, and multiple cancer-related signaling pathways. Additionally, <i>CRISPR</i> gene knockout experiments confirmed that TMPO knockout significantly inhibited the proliferation of PTC cell lines, indicating its important role in tumor growth.</p><p><strong>Conclusion: </strong>TMPO is overexpressed in PTC and may serve as a therapeutic target and molecular biomarker for PTC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107109"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton pump inhibitors and mortality in patients with cancer: Unraveling the complex link.","authors":"Ibtehaj Tariq, Qurat Ul Ain Iftikhar, Abdulqadir J Nashwan","doi":"10.5306/wjco.v16.i7.107509","DOIUrl":"10.5306/wjco.v16.i7.107509","url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) are widely utilized in oncology to treat gastroesophageal reflux disease, peptic ulcer disease, and chemotherapy-induced mucosal injury. Emerging evidence has suggested that prolonged use of PPIs is associated with increased mortality in patients with cancer. The findings of Krishnan <i>et al</i> are proof of this but need to be considered cautiously due to potential confounding factors. This letter raised important methodological concerns, including confounding by indication, reverse causality, and polypharmacy that can influence the observed association. While PPIs are important in oncology, their advantages and disadvantages should be weighed judiciously by clinicians. Future prospective studies with robust analytical approaches will be required to ascertain more definite causality.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107509"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosmarinic acid as a targeted modulator of NF-κB signaling in colorectal cancer: A promising adjunct to chemotherapy.","authors":"Md Sadique Hussain, Amita Joshi Rana, Sumel Ashique, Vikash Jakhmola, Gaurav Gupta","doi":"10.5306/wjco.v16.i7.108086","DOIUrl":"10.5306/wjco.v16.i7.108086","url":null,"abstract":"<p><p>We commend the work of Liu <i>et al</i>, who provide compelling preclinical evidence that rosmarinic acid (RA), a natural dietary polyphenol, exerts potent anti-tumor effects in colorectal cancer (CRC) by selectively suppressing the NF-κB signaling pathway. The study's integrative approach-encompassing molecular docking, transcriptional analysis, and apoptosis induction-demonstrates RA's ability to inhibit key oncogenic mediators, including cyclin D1 and MYC. Notably, RA enhances the efficacy of chemotherapeutics such as 5-fluorouracil and oxaliplatin synergistically, suggesting its potential as a chemosensitizer to overcome resistance. Given RA's established safety profile and its broad spectrum of biological activities, this study provides a strong rationale for advancing RA toward translational applications in CRC management. We highlight the relevance of this work in the broader context of natural compound-based therapeutics and inflammation-driven tumor biology.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108086"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unleashing the potential of ferroptosis, autophagy, and mitochondrial dynamics as emerging modalities in cancer treatment.","authors":"Tanha Ashok Rana, Akhilesh Prajapati","doi":"10.5306/wjco.v16.i7.107788","DOIUrl":"10.5306/wjco.v16.i7.107788","url":null,"abstract":"<p><p>New approaches in cancer treatment are increasingly emphasizing innovative biological processes such as ferroptosis, autophagy, and mitochondrial dynamics. Ferroptosis, characterized by iron-dependent lipid peroxidation, has emerged as a promising strategy for targeting aggressive and metastatic cancers including those of the lung, breast, prostate, pancreas, and colorectal regions. Autophagy, a cellular degradation mechanism, plays a dual role in cancer-it can inhibit tumor development by clearing damaged cellular components or, paradoxically, support tumor growth under stressful conditions. Mitochondrial dynamics, encompassing the continuous processes of fission and fusion, are often disrupted in various types of human cancers, leading to altered metabolism, therapy resistance, and metastasis. These disruptions make them favorable targets for innovative treatments. This review highlights ferroptosis as a novel form of cell death, focusing on its biological pathways and connections with mitochondrial dysfunction and autophagy. Understanding the interplay among these three mechanisms in the complex biology of cancer could provide a more comprehensive and effective approach to cancer therapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107788"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}